NASDAQ: ACBAurora Cannabis Inc Stock
$2.93+0.01 (+0.34%)
Updated Jun 18, 2026
ACB Price
$2.93
Fair Value Price
N/A
Market Cap
$172.72M
52 Week Low
$2.73
52 Week High
$6.67
P/E
-1.89x
P/B
0.47x
P/S
0.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$232.31M
Earnings
-$119.11M
Gross Margin
42.6%
Operating Margin
-50.05%
Profit Margin
-51.3%
Debt to Equity
0.17
Operating Cash Flow
-$10M
Beta
1.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACB Overview
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACB's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ACB
Ranked#49 of 50
Ranked#49 of 50
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $158.29 | A | |
| $38.30 | A | |
| $33.54 | A |
Be the first to know about important ACB news, forecast changes, insider trades & much more!
ACB News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ACB is good value based on its book value relative to its share price (0.47x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.51x)
P/B vs Industry Valuation
ACB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ACB due diligence checks available for Premium users.
Valuation
ACB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.89x
Industry
-5.43x
Market
9.47x
ACB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.47x
Industry
1.51x
ACB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACB's financial health
Profit margin
Revenue
$27.5M
Net Income
-$50.5M
Profit Margin
-183.2%
ACB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ACB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$435.6M
Liabilities
$64.7M
Debt to equity
0.17
ACB's short-term assets ($288.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACB's short-term assets ($288.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ACB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$166.7k
Investing
-$3.8M
Financing
$9.7M
ACB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACB vs Pharmaceutical Stocks
Aurora Cannabis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.